News

November 01, 2023 Company

Ono Pharmaceutical Co., Ltd. Announced 2023 2Q Financial Results
September 27, 2023 Licensing

Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field
August 31, 2023 Licensing

Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune Diseases
July 31, 2023 Company

Ono Pharmaceutical Co., Ltd. Announced 2023 1Q Financial Results
May 10, 2023 Company

Ono Pharmaceutical Co., Ltd. Announced 2022 Full Year Financial Results
April 18, 2023 Company

ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs
March 22, 2023 R & D

ONO PHARMA USA’s Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma
February 24, 2023 Licensing

Ono Pharmaceutical Co., Ltd. Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein
February 17, 2023 Company

Ono Pharmaceutical Co., Ltd. Supports for Relief Efforts in the Earthquake in Turkey and Syria
January 31, 2023 Company

Ono Pharmaceutical Co., Ltd. Announced 2022 3Q Financial Results
January 25, 2023 Licensing

Ono Pharmaceutical Co., Ltd. Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics
December 27, 2022 Sustainability

Ono Pharmaceutical Co., Ltd. Selected for the DJSI World Index and DJSI Asia Pacific Index for Three Straight Years
December 27, 2022 Sustainability

Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2022
December 06, 2022 Licensing

Ono Pharmaceutical Co., Ltd. and Equillium Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
October 31, 2022 Company

Ono Pharmaceutical Co., Ltd. Announced 2022 2Q Financial Results
August 31, 2022 Company

ONO PHARMA USA continues to expand its organization for enhancement of R&D activities and future commercialization opportunities in the U.S.
August 29, 2022 R & D

ONO PHARMA USA Initiated Phase 1 Study of ONO-7018, a MALT1 Inhibitor,in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
August 01, 2022 Company

Ono Pharmaceutical Co., Ltd. Announced 2022 1Q Financial Results
May 11, 2022 Company

Ono Pharmaceutical Co., Ltd. Announced 2021 Full Year Financial Results
January 31, 2022 Company

Ono Pharmaceutical Co., Ltd. Announced 2021 3Q Financial Results
December 15, 2021 Sustainability

Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2021
November 01, 2021 Company

Ono Pharmaceutical Co., Ltd. Announced 2021 2Q Financial Results
October 19, 2021 R & D

ONO PHARMA USA Announces Initiation of Phase 1 Study of ONO-4685, an Anti-PD-1/CD3 Bispecific Antibody, in Patients with Relapsed or Refractory T-cell Lymphoma in the U.S (108KB)
September 28, 2021 Company

ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership (112KB)
July 30, 2021 Company

Ono Pharmaceutical Co., Ltd. Announced 2021 1Q Financial Results
July 19, 2021 R & D

ONO PHARMA USA Announces the Initiation of Phase 2 Study of Tirabrutinib, a BTK Inhibitor, in Patients with Primary Central Nervous System Lymphoma (110KB)
May 11, 2021 Company

Ono Pharmaceutical Co., Ltd. Announced 2020 Full Year Financial Results
April 27, 2021 Company

Announcement of New Office Establishment (318KB)
March 26, 2021 Company

Ono Pharmaceutical Co., Ltd. Joins the University of California Drug Discovery Consortium
March 17, 2021 Company

Ono Pharmaceutical Co., Ltd. Entered Sponsorship Agreements with LabCentral and MBC BioLabs
February 01, 2021 Company

Ono Pharmaceutical Co., Ltd. Announces 2020 3Q Financial Results
December 25, 2020 Company

ONO PHARMA USA launches a new website. (316KB)